Abstract: The present invention provides a controllably degradable cationic polymer for delivery of biomolecules (nucleic acids, peptides, etc.), drugs, molecules used in medical imaging applications, sensitizing agents used in cancer treatments, and molecules used in tissue engineering. The present invention also provides a method for synthesizing the polymer according to the present invention.
Type:
Application
Filed:
October 11, 2002
Publication date:
November 20, 2003
Inventors:
Lei Yu, Fusheng Du, Shouping Ji, Kenji Matsumoto
Abstract: Iron binding polymers are provided for decreasing the absorption of iron from the gastrointestinal tract. The polymers are orally administered, and are useful for treatment of iron overload disorders.
Type:
Grant
Filed:
September 6, 2000
Date of Patent:
August 12, 2003
Assignee:
Genzyme Corporation
Inventors:
W. Harry Mandeville, III, Stephen Randall Holmes-Farley
Abstract: Phosphate-binding polymers are provided for removing phosphate from the gastrointestinal tract. The polymers are orally administered, and are useful for the treatment of hyperphosphatemia.
Type:
Application
Filed:
December 17, 2002
Publication date:
July 17, 2003
Applicant:
GelTex Pharmaceuticals, Inc.
Inventors:
Stephen Randall Holmes-Farley, W. Harry Mandeville, George M. Whitesides
Abstract: The present invention relates to iodine demand disinfectants. It relates in particular to a process for preparing a polyiodide-resin for use as an iodine demand disinfectant wherein a porous strong base anion exchange resin in a salt form, is contacted with a material capable of donating a member absorbable by the resin so as to convert the resin to the polyiodide-resin. The adsorbable member is selected from the group comprising I2 and polyiodide ion having a valence of −1. The process is characterized in that conversion of the anion exchange resin to the polyiodide-resin is effected at elevated temperature and elevated pressure, the elevated temperature being 100 degrees C. or higher, the elevated pressure being greater than atmospheric pressure. The present invention also relates to disinfectant substance comprising an iodine (impregnated) resin as produced by the above process.
Abstract: This invention relates to the formulation of oral liquid products of quinolones or derivatives thereof using ion exchange resins, such as methacrylic acid polymer crosslinked with divinylbenzene, as the carrier, thereby eliminating the extreme bitterness of the quinolones oral liquid formulation.
Type:
Grant
Filed:
July 12, 2000
Date of Patent:
February 4, 2003
Assignee:
Schering-Plough Veterinary Corporation
Inventors:
Rong Gao, Zezhi Jesse Shao, Allan Chor-Lun Fan, Leonore Catherine Witchey-Lakshmanan, Daniel Charles Stewart
Abstract: Biocompatible hydrogels, for: scaffoldings for tissue engineering; cell encapsulation matrices; injectable bulking materials for cosmetic and functional restorations; controlled release matrices; gene delivery vehicles; immunoprotection matrices; immobilization materials; food additives; medical gels; conductive electrode gels; lubricious coatings; film forming creams; membranes; superabsorbents; hydrophilic coatings; and wound dressings. The hydrogels include: at least one water-soluble polymer/copolymer; and at least one slow and/or fast dissolving and/or releasing divalent and/or multivalent cation-containing compound. At least one of the monomers is an acid, and/or contains an acid group or a derivative thereof. Such monomer reacts with the cations to form a three-dimensional ionically crosslinked hydrogel composition.
Type:
Grant
Filed:
December 1, 1999
Date of Patent:
December 24, 2002
Assignee:
The Regents of the University of Michigan
Abstract: Sustained delivery pharmaceutical compositions comprising a solid ionic complex of a pharmaceutically active compound and an ionic macromolecule are provided by the present invention. The pharmaceutical compositions of the invention allow for loading of high concentrations of pharmaceutically active compounds and for delivery of a pharmaceutically active compound for prolonged periods of time, e.g., one month, after administration. Methods for preparing these pharmaceutical compositions, as well as methods of using them to treat a subject are also provided.
Abstract: A dosage form is described that gives an extended release of active ingredients using unloaded ion exchange resins, that does not require the manufacture of a resinate.
Type:
Application
Filed:
March 26, 2002
Publication date:
November 28, 2002
Inventors:
Lyn Hughes, Simon Andrew Bellamy, Christina Hann
Abstract: There are provided an adsorbent which can effectively adsorb and remove endogenous cannabinoid in fluid, and a process for removing endogenous cannabinoid in fluid by means of the adsorbent. The adsorbent of endogenous cannabinoid is obtained by fixing a compound having a log P value (P indicating distribution coefficient in octanol-water system) of at least 3.50 on a water-insoluble carrier. Endogenous cannabinoid in fluid can be adsorbed and removed in an effective manner by contacting the adsorbent of endogenous cannabinoid with fluid containing endogenous cannabinoid.
Abstract: A dosage form comprising a resin/resinate combination is described. Said dosage form allows optimization of the release rate profile of active ingredients.
Type:
Application
Filed:
March 26, 2002
Publication date:
October 10, 2002
Inventors:
Lyn Hughes, Simon Andrew Bellamy, Christina Hann
Abstract: The present invention relates to a method for sequestering bile acids in a patient and to particular polymers for use in the method. The method comprises administering a therapeutically effective amount of a guanidinium moiety-containing polymer composition to a mammal, such as a human, whereby bile acids are sequestered.
The polymers of the invention comprise guanidinium moieties and optionally, additional substituents such as a hydrophobic group, a quaternary ammonium-containing group or a combination thereof.
Type:
Grant
Filed:
October 2, 1998
Date of Patent:
September 25, 2001
Assignee:
GelTex Pharmaceuticals, Inc.
Inventors:
Pradeep K. Dhal, Stephen R. Holmes-Farley, John S. Petersen
Abstract: A method for treating pathogenic toxins in a mammal, such as a human, comprising treating the mammal with a therapeutically effective amount of a polymer comprising a cationic group attached to the polymer backbone. The polymer can be a homopolymer or a copolymer. In one embodiment, the polymer is a copolymer comprising a monomer having a pendant ammonium group and a hydrophobic monomer.
Type:
Grant
Filed:
June 19, 2000
Date of Patent:
September 18, 2001
Assignee:
GelTex Pharmaceuticals, Inc.
Inventors:
Richard Fitzpatrick, Chad Cori Huval, Caroline Isabelle Bacon Kurtz, W. Harry Mandeville, III, Thomas X. Neenan
Abstract: A method for reducing oxalate levels in a patient that includes administering to the patient a therapeutically effective amount of non-absorbable amine polymers such as a polymer characterized by a repeat unit having the formula:
and salts and copolymers thereof, where n is a positive integer and x is zero or an integer between 1 and about 4.
Type:
Grant
Filed:
September 25, 2000
Date of Patent:
August 28, 2001
Assignee:
GelTex Pharmaceutical, Inc.
Inventors:
Stephen Randall Holmes-Farley, W. Harry Mandeville, III
Abstract: A sustainedly releasing agent for medicines comprising a non-crosslinked type anion-exchange resin represented by the general formula (I):
wherein
R1 represents aralkyl or alkyl, each of R2 and R3 represents lower alkyl, R4 represents a hydrogen atom or lower alkyl, X− represents a physiologically acceptable counter ion, n represents 1-3, and p represents a mean degree of polymerization, respectively, as well as a sustainedly released medicinal composition comprising the sustainedly releasing agent and a hypolipidemic agent.
Abstract: A medicament which comprises as an active ingredient a weakly basic anion exchange resin chelating with ferric ions, preferably a polyamine-type or an acrylic-type resin. The medicament has excellent adsorbability and selectivity to phosphate ions and efficiently adsorb phosphate ions in vivo, and accordingly, is useful for therapeutic and/or preventive treatment of hyperphosphatemia.